share_log

Ambrx Provides Update On APEX-01, An On-Going Phase 1/2 Dose Escalation Study Evaluating ARX517, A Proprietary PSMA-Targeting ADC, In Metastatic Castration-Resistant Prostate Cancer

Benzinga ·  Nov 28, 2023 21:21
  • Following completion of the 21-day observation period at 3.4 mg/kg (Cohort 9), no dose limiting toxicities (DLTs) or serious adverse events (SAEs) were observed
  • Two patients in Cohort 9 experienced rapid PSA reduction at three weeks post-treatment following the first ARX517 dose

Cohort 8

  • The cohort (2.88 mg/kg) is now fully enrolled with 20 patients

Recommended phase 2 dose expected by early next year

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment